0
Signin
countryflagUS

18889881171

MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%

Zivo Bioscience Inc

Healthcare US ZIVO

8.45USD
-(-%)

Last update at 2024-07-24T13:30:00Z

Day Range

8.458.45
LowHigh

52 Week Range

0.4817.82
LowHigh

Fundamentals

  • Previous Close 8.45
  • Market Cap22.60M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.03M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 0.02M
  • Diluted EPS TTM-3.81

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -8.74529M -9.16337M -9.10573M -11.51017M -14.63537M
Minority interest - - - - -
Net income -8.74529M -9.39665M -9.65578M -14.66798M -14.63537M
Selling general administrative 6.49M 6.93M 4.82M 6.05M 3.32M
Selling and marketing expenses - - - - -
Gross profit - - 0.02M - 0.00000M
Reconciled depreciation - - - - 0.00000M
Ebit -8.73197M -9052.60500M -9.10573M -8.35235M -6.13064M
Ebitda -8.73197M -9.05260M -8.55568M -8.35235M -6.53813M
Depreciation and amortization - -0.55575M 0.00062M - -0.40749M
Non operating income net other - - - -3.15782M -8.50472M
Operating income -8.73197M -9.05260M -8.55568M -8.35235M -6.13064M
Other operating expenses 8.73M 9.05M 8.58M 8.35M 6.13M
Interest expense 0.01M 0.23M 0.55M 3.16M 8.10M
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.01332M -0.23328M -0.55005M -3.15782M -8.50472M
Extraordinary items - - - - -
Non recurring - - 2.87M 1.97M 1.96M
Other items - - - - -
Income tax expense - 0.23M 0.55M 3.16M 0.41M
Total revenue 0.00000M 0.00000M 0.02M 0.00000M 0.00000M
Total operating expenses 8.73M 9.05M 8.58M 8.35M 6.13M
Cost of revenue - - - - 0.00000M
Total other income expense net -0.01332M -0.11076M -0.55005M -3.15782M -8.50472M
Discontinued operations - - - - -
Net income from continuing ops -8.74529M -9.16337M -9.10573M -11.51017M -14.63537M
Net income applicable to common shares -8.74529M -9.16337M -9.10573M -11.51017M -14.63537M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 0.56M 2.12M 8.99M 0.22M 0.37M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.15M 0.10M 58.08M 29.95M 0.02M
Total liab 2.76M 2.13M 2.95M 11.53M 8.71M
Total stockholder equity -2.20584M -0.01062M 6.04M -11.31061M -8.33848M
Deferred long term liab - - - - -
Other current liab 1.66M 1.20M 2.04M 2.68M 2.06M
Common stock 0.00238M 0.00942M 0.00942M 0.41M 0.40M
Capital stock 0.00238M 0.00942M 0.00942M 0.41M 0.40M
Retained earnings -123.58171M -115.80453M -108.22704M -99.06368M -89.95795M
Other liab - - - - -
Good will - - - - -
Other assets - 0.03M 0.00300M 0.00300M -
Cash 0.27M 1.80M 8.90M 0.14M 0.35M
Cash and equivalents - - - - -
Total current liabilities 2.76M 2.03M 2.95M 11.39M 8.71M
Current deferred revenue -0.24000M - - 1.94M -
Net debt 0.07M -1.35408M -8.64670M 5.22M 4.93M
Short term debt 0.35M 0.34M 0.26M 5.22M 5.28M
Short long term debt 0.24M 0.24M 0.24M 5.19M 5.28M
Short long term debt total 0.35M 0.45M 0.26M 5.36M 5.28M
Other stockholder equity 121.37M 115.78M 114.26M 87.34M 81.22M
Property plant equipment - 0.19M 0.03M 0.05M -
Total current assets 0.43M 1.90M 8.96M 0.17M 0.37M
Long term investments - - - - -
Net tangible assets - -0.01062M 6.04M -11.31061M -8.33848M
Short term investments - - - - -
Net receivables 0.00374M - - - -
Long term debt - - - 0.12M -
Inventory - - - - -
Accounts payable 0.99M 0.49M 0.65M 1.56M 1.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.10000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.41M 0.40M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -99.06368M -89.95795M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.03M 0.00300M 0.00300M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.13M 0.22M 0.03M 0.05M 0.00000M
Capital lease obligations 0.11M 0.21M 0.02M 0.04M -
Long term debt total - - - 0.12M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to liabilities -0.16366M -0.81999M 0.84M 0.95M -0.11929M
Total cashflows from investing activities - - - - -
Net borrowings - - 0.25M 0.03M 1.75M
Total cash from financing activities -0.62860M 15.57M 2.38M 3.66M 5.08M
Change to operating activities -0.19173M 0.43M 0.64M 1.52M 2.05M
Net income -8.74529M -9.16337M -9.10573M -11.51017M -14.63537M
Change in cash -7.10261M 8.76M -0.20825M -0.04278M 0.07M
Begin period cash flow 8.90M 0.14M 0.35M 0.39M 0.32M
End period cash flow 1.80M 8.90M 0.14M 0.35M 0.39M
Total cash from operating activities -7.10261M -6.80333M -2.58841M -3.70730M -5.00659M
Issuance of capital stock 0.00000M 17.21M 0.40M 2.65M 3.43M
Depreciation -0.77402M -555.74500M 0.00062M 1.19M 5.09M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 0.40M 2.65M 3.43M
Other cashflows from financing activities 0.63M -1.45163M 1.98M 1.05M 1.86M
Change to netincome 2.00M 2.75M 3.85M 0.76M 0.82M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - 1.83M 0.00067M 0.00747M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -0.20825M -0.04278M 0.07M
Change in working capital -0.35539M -0.39413M 2.67M 2.47M 1.93M
Stock based compensation 2.69M 3.38M - - -
Other non cash items 0.08M -0.62335M 3.85M 4.15M 2.61M
Free cash flow -7.10261M -6.80333M -2.58841M -3.70730M -5.00659M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZIVO
Zivo Bioscience Inc		 - -% 8.45 - - 803.66 21.13 806.26 -3.0694
NVO
Novo Nordisk A/S		 -2.29 1.74% 129.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.80 2.90% 135.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.67 0.75% 494.48 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 22.92 2.16% 1083.78 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Zivo Bioscience Inc

21 East Long Lake Road, Bloomfield Hills, MI, United States, 48304

Key Executives

Name Title Year Born
Mr. John B. Payne Pres, CEO & Chairman 1948
Mr. Keith R. Marchiando CFO, Treasurer & Sec. 1962
Mr. John B. Payne President, CEO & Chairman of the Board 1948
Mr. Keith R. Marchiando CFO, Treasurer & Secretary 1962
Dr. Harlan L. Miller III Vice President of Technology & Global Supply NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.